Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$144.13 USD
-1.50 (-1.03%)
Updated Aug 7, 2024 03:59 PM ET
After-Market: $144.02 -0.11 (-0.08%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Brokerage Reports
Neurocrine Biosciences, Inc. [NBIX]
Reports for Purchase
Showing records 1 - 20 ( 312 total )
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Crinecerfont Snags Priority Review, No AdCom -- Sets Up Interesting 2025
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Passing The Torch: NBIX Announces CEO Succession Plan
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Expectations Surrounding PANSS Scale for NBI-568?s Phase 2 Readout; PT Up to $160
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Solid Ingrezza Performance, As Additional Pipeline Readouts On Deck
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Positive Topline SAVITRI Data Set Up NBI-845 for Potential Win in MDD
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Nice Pipeline Win Heading Into Earnings; ''845 MDD Hits
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Focusing on Importance of PK and Safety for Topline Data of ?568?Our Thoughts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Onward As NBIX Sets Stage With FY24 Guidance, Near-Term Crinecerfont Filing
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Kickstart or False Start? What January Tells Us about Biotech Annual Returns
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Neurocrine Shifts Focus Towards Neurology, Eyeing at Movement Disorder Diseases and Psychosis
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
If Cash Is King In Biotech, Pipelines Are The Queens
Provider: Wedbush Securities Inc.
Analyst: CHICO L